Cetuximab
Patients With Advanced or Metastatic Solid Tumors
Gustave Roussy, Cancer Campus, Grand Parismonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Patients With Advanced or Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Temsirolimus Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 | CC |
Eloxatin Disphar International B.V. | Phase 1 | CC |
Epirubicin Disphar International B.V. | Phase 1 | CC |
S-1 Disphar International B.V. | Phase 1 | CC |
Same molecule, other indications
Cetuximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →